NEW YORK, July 27, 2021 (GLOBE NEWSWIRE) -- Clever Leaves Holdings Inc. (NASDAQ: CLVR, CLVRW) (“Clever Leaves” or the “Company”), a leading multinational operator and licensed producer of pharmaceutical-grade cannabinoids, and Biopharmaceutical Research Company (“BRC”), a specialty pharmaceutical company that holds federal licenses for importing, analyzing and manufacturing controlled substances in the U.S., today announced a joint partnership with the intent to study the DNA sequence variation of three Clever Leaves’ cannabis cultivars as part of their Project Change Lives campaign. The University of California, Davis (“UC Davis”), through an accepted research sponsorship from BRC, will lead the extraction and analysis of DNA to elucidate genetic variants taken from various genetic lines of Cannabis sativa.
- The initiative is part of Project Change Lives; Clever Leaves $25M product pledge to aid cannabis research in the U.S.
- UC Davis will be the first major research institution to collaborate in the investigation of Clever Leaves Colombian and Portuguese, pharmaceutical-grade cannabis as part of Project Change Lives.
- We are honored to collaborate with the UC Davis Plant Science department, said Kyle Detwiler, CEO of Clever Leaves.
- To eliminate an additional impediment to the advancement of scientific knowledge around cannabis, this research material will be provided at no cost to Clever Leaves research partners.